JAHA:接受PCI治疗的退伍军人对高强度他汀类药物治疗的依从性研究

2018-03-05 MedSci MedSci原创

2013年美国心脏病协会的指南推荐了一部分人群接受高强度他汀类药物治疗,但是患者对指南的依从性不佳。本研究旨在评估接受过经皮冠脉介入治疗(PCI)退伍军人接受高强度他汀类药物治疗的趋势和预测因素。本研究纳入了2010年至2016年接受过PCI治疗的年龄>18岁的退伍军人,并对其人口统计学特征、并发症和PCI前后90天内的他汀类药物类型和剂量进行分析。最终共纳入了48862名退伍军人,PCI术后90

2013年美国心脏病协会的指南推荐了一部分人群接受高强度他汀类药物治疗,但是患者对指南的依从性不佳。本研究旨在评估接受过经皮冠脉介入治疗(PCI)退伍军人接受高强度他汀类药物治疗的趋势和预测因素。

本研究纳入了2010年至2016年接受过PCI治疗的年龄>18岁的退伍军人,并对其人口统计学特征、并发症和PCI前后90天内的他汀类药物类型和剂量进行分析。最终共纳入了48862名退伍军人,PCI术后90天内接受高强度他汀类药物治疗的比例从2010年的23%骤升至2016年的80%,与接受中低等强度他汀类药物治疗的患者相比,接受高强度他汀类药物治疗的患者10年动脉粥样硬化性心血管事件的发生要减少约1841件。

研究结果显示,截至2016年,接受有PCI治疗的退伍军人对2013年指南中推荐接受高强度他汀类药物治疗的依从性较好。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044496, encodeId=f494204449603, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Oct 03 10:17:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648679, encodeId=c04a16486e94c, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Sat Jul 07 19:17:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030095, encodeId=8fce2030095f9, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Jan 27 13:17:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296248, encodeId=629a296248fe, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47822294130, createdName=121f16f3m79暂无昵称, createdTime=Wed Mar 14 22:26:43 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267755, encodeId=274b126e75528, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319311, encodeId=adf81319311cf, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604016, encodeId=6c3616040161d, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293193, encodeId=f9b029319376, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Mar 05 09:26:33 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044496, encodeId=f494204449603, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Oct 03 10:17:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648679, encodeId=c04a16486e94c, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Sat Jul 07 19:17:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030095, encodeId=8fce2030095f9, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Jan 27 13:17:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296248, encodeId=629a296248fe, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47822294130, createdName=121f16f3m79暂无昵称, createdTime=Wed Mar 14 22:26:43 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267755, encodeId=274b126e75528, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319311, encodeId=adf81319311cf, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604016, encodeId=6c3616040161d, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293193, encodeId=f9b029319376, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Mar 05 09:26:33 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044496, encodeId=f494204449603, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Oct 03 10:17:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648679, encodeId=c04a16486e94c, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Sat Jul 07 19:17:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030095, encodeId=8fce2030095f9, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Jan 27 13:17:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296248, encodeId=629a296248fe, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47822294130, createdName=121f16f3m79暂无昵称, createdTime=Wed Mar 14 22:26:43 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267755, encodeId=274b126e75528, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319311, encodeId=adf81319311cf, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604016, encodeId=6c3616040161d, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293193, encodeId=f9b029319376, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Mar 05 09:26:33 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2044496, encodeId=f494204449603, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Oct 03 10:17:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648679, encodeId=c04a16486e94c, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Sat Jul 07 19:17:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030095, encodeId=8fce2030095f9, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Jan 27 13:17:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296248, encodeId=629a296248fe, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47822294130, createdName=121f16f3m79暂无昵称, createdTime=Wed Mar 14 22:26:43 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267755, encodeId=274b126e75528, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319311, encodeId=adf81319311cf, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604016, encodeId=6c3616040161d, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293193, encodeId=f9b029319376, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Mar 05 09:26:33 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-03-14 121f16f3m79暂无昵称

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2044496, encodeId=f494204449603, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Oct 03 10:17:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648679, encodeId=c04a16486e94c, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Sat Jul 07 19:17:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030095, encodeId=8fce2030095f9, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Jan 27 13:17:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296248, encodeId=629a296248fe, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47822294130, createdName=121f16f3m79暂无昵称, createdTime=Wed Mar 14 22:26:43 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267755, encodeId=274b126e75528, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319311, encodeId=adf81319311cf, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604016, encodeId=6c3616040161d, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293193, encodeId=f9b029319376, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Mar 05 09:26:33 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-03-07 zhaohui6731
  6. [GetPortalCommentsPageByObjectIdResponse(id=2044496, encodeId=f494204449603, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Oct 03 10:17:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648679, encodeId=c04a16486e94c, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Sat Jul 07 19:17:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030095, encodeId=8fce2030095f9, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Jan 27 13:17:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296248, encodeId=629a296248fe, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47822294130, createdName=121f16f3m79暂无昵称, createdTime=Wed Mar 14 22:26:43 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267755, encodeId=274b126e75528, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319311, encodeId=adf81319311cf, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604016, encodeId=6c3616040161d, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293193, encodeId=f9b029319376, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Mar 05 09:26:33 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-03-07 fyxzlh
  7. [GetPortalCommentsPageByObjectIdResponse(id=2044496, encodeId=f494204449603, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Oct 03 10:17:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648679, encodeId=c04a16486e94c, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Sat Jul 07 19:17:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030095, encodeId=8fce2030095f9, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Jan 27 13:17:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296248, encodeId=629a296248fe, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47822294130, createdName=121f16f3m79暂无昵称, createdTime=Wed Mar 14 22:26:43 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267755, encodeId=274b126e75528, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319311, encodeId=adf81319311cf, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604016, encodeId=6c3616040161d, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293193, encodeId=f9b029319376, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Mar 05 09:26:33 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-03-07 aids219
  8. [GetPortalCommentsPageByObjectIdResponse(id=2044496, encodeId=f494204449603, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Oct 03 10:17:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648679, encodeId=c04a16486e94c, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Sat Jul 07 19:17:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030095, encodeId=8fce2030095f9, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Jan 27 13:17:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296248, encodeId=629a296248fe, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47822294130, createdName=121f16f3m79暂无昵称, createdTime=Wed Mar 14 22:26:43 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267755, encodeId=274b126e75528, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319311, encodeId=adf81319311cf, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604016, encodeId=6c3616040161d, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Wed Mar 07 00:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293193, encodeId=f9b029319376, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Mon Mar 05 09:26:33 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-03-05 神功盖世

    0

相关资讯

JAHA:冠脉搭桥术后6-12h的cTnT水平能预测患者预后

心肌肌钙蛋白T(cTnT)水平会在冠脉搭桥术后常规检测。本研究的目的旨在评估cTnT水平与冠脉搭桥术后6-12小时预后的关系。本研究纳入了1722名接受孤立性冠脉搭桥术的患者,评估了749名患者的传统cTnT水平和973名患者的高敏cTnT(hs-cTnT)水平与术后6-12小时主要心脑血管不良事件(MACCE)的发生的相关性。在传统cTnT评估组,有92名(12%)患者出现了MACCE,在hs-

Lancet Diabetes Endo:高比例的前驱糖尿病患者患心血管疾病和慢性肾脏疾病的风险更高

埃默里罗林斯公共卫生学院和美国疾病控制和预防中心的研究人员发现,高比例的前驱糖尿病患者患心血管疾病和慢性肾脏疾病的风险很高。他们的研究结果发表在“柳叶刀糖尿病与内分泌学”上。

JACC:行Fontan手术存活至成年的患者预后如何?

对于存活至16岁及以上的接受Fontan手术患者的临床预后尚未阐明。本研究的目的旨在评估接受Fontan手术治疗的成年患者的临床预后。本研究纳入了澳大利亚和新西兰Fontan注册数据库(ANZFR)中年龄≥16岁的患者。最终共纳入分析了683名成年幸存者,有201名患者存在心房肺动脉(AP)交通,482名患者存在全腔静脉肺动脉交通。对于这些患者,30岁的存活率为90%(95% CI: 87%-93

Eur Heart J:PCSK9基因的突变对卒中和冠心病有不同的影响

PCSK9基因的突变对低密度脂蛋白胆固醇(LDL-C)和冠心病的发生均有很大的影响,然而其对缺血性卒中(IS)的影响尚属未知。本研究对10307名IS患者和19326名正常对照对PCSK9功能缺失突变(rs11591147; R46L)和另外5个突变位点与IS和IS亚型之间的关系进行荟萃分析。结果发现rs11591147的T等位点可以降低0.5mmol/L 的LDL-C水平和23%的冠心病发病风险

Heart:抗磷脂抗体可预测感染性心内膜炎患者预后

抗磷脂(aPL)抗体可以激活血小板,并在感染性心内膜炎(IE)的发展和血栓形成中起到重要作用。本研究的目的旨在评估aPL作为预测IE患者血栓事件(EE)发生的因子的可行性。本研究纳入了Nanc-IE数据库中的186名确诊为IE的患者,在患者入组后对其进行抗心磷脂(aCL)和抗β2-糖蛋白I(β2GPI)抗体的检测。分析结果发现,在118名(63%)患者中检测到至少一次EE的发生,在31名(17%)

JAHA:心脏的康复训练能改善腹部动脉瘤患者预后

目前尚无报道阐述体育锻炼对小型腹部动脉瘤(AAA)患者的影响。本研究纳入了2004年至2015年1515名小型AAA的术前患者,一种精心调整的心脏康复方案被应用在50名患者中,并且在运动过程中没有过高的血压升高。最终评估心脏康复组和非康复组患者的死亡率和临床预后(包括动脉瘤的扩张率)的差异。心脏康复组患者(n=49)和非康复组(n=163)的人口统计学特征一致。分析结果发现AAA修复的风险在康复组